Diplomat Pharmacy (DPLO) Tops Q3 EPS by 10c, Miss on Revenues; FY17 EPS Guidance Above Consensus

Diplomat Pharmacy (DPLO) PT Raised to $24 at Needham & Company; 'Solid Quarter, CVS Settlement & PBM Acquisition'

Needham & Company raised its price target on Diplomat Pharmacy (NYSE: DPLO) to $24.00 (from $23.75) while maintaining a Buy rating, following the company's acquisition of a small national PBM.

Analyst Kevin Caliendo increases price target on the shares, as the company reported third quarter earnings per... More

Diplomat Pharmacy (DPLO) PT Raised to $20 at Mizuho Securities on 3Q Beat & Raise; 'New DIR Agreement De-Risks Shares'

Mizuho Securities raised its price target on Diplomat Pharmacy (NYSE: DPLO) to $20.00 (from $16.00) while maintaining a Neutral rating, following the company's third quarter earnings report.

Analyst Ann Hynes notes a positive outlook on the shares, as the company reported third quarter earnings per... More

Diplomat Pharmacy (DPLO) PT Raised to $20 at Leerink Partners

Leerink Partners raised its price target on Diplomat Pharmacy (NYSE: DPLO) to $20.00 (from $16.00) while maintaining a Market Perform rating following mixed results.

Analyst David Larsen notes that DPLO also announced the acquisition of National Pharmaceutical Services, a PBM focused on small to mid-sized... More

Diplomat Pharmacy (DPLO) to Acquire National Pharmaceutical Services

Diplomat Pharmacy, Inc. (NYSE: DPLO), has entered into a definitive agreement to acquire Pharmaceutical Technologies, Inc., doing business as National Pharmaceutical Services. The transaction is expected to close in 30 days.

National Pharmaceutical Services (NPS) is a full-service pharmacy benefit manager (PBM) based in Omaha, Nebraska. It features a proprietary claims-processing system and offers mail-order service under its Integrated HMO Pharmacy.

"Industry dynamics and the evolution of our payor strategy have accelerated our push to add PBM-like services,"... More